3STONE G W, MOLITERNO D J, BERTRAND M,et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein Ⅱb/Ⅲa in hibitors inpatients undergoing coronary stenting the TARGET trial[J]. Circulation, 2002,105 ：2345- 2354. 被引量：1
4CROUCH M A, NAPPI J M, CHEANG K I. Glycoprotein Ⅱb/Ⅲa receptor inbibitors in percutan coronary intervention and acute coronary syndrome [J].Ann Pharmacother, 2003, 37: 860-875. 被引量：1
5FUSTER V, BADIMON L, BADIMON J J, et al.The pathogenesis of coronary artery disease and the acute coronary syndromes [J]. N Engl J Med, 1992,326: 242- 250. 被引量：1
6The Restore Investigators. Effects of platelet Glycoprotein Ⅱb/Ⅲa Blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J]. Circulation ,1997, 96: 1445-1453. 被引量：1
7The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲ a receptor with tirofiban in unstable angina and non-Q-wave rnyocardial infarction[J]. N Engl J Med, 1998, 338:1488-1497. 被引量：1
8BOERSMA E, HARRINGTON R A, MOLITERNO D J, et al. Platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J]. Lancet, 2002, 359:189-198. 被引量：1
9TCHENG J E, ELLIS S G, GEORGE B S, et al.Pharmacodynamics of chimetic glycoprotein Ⅱb/Ⅲa integrin antiplatelet antibody Fab TEs in high-risk coronary angioplasty[J]. Circulation, 1994, 90:1757-1764. 被引量：1
